Recombinant Rat TMEM176A is synthesized using mammalian expression systems (e.g., HEK293 cells) or E. coli . Key production parameters include:
Custom production options are available for specific experimental needs, with lead times of 5–9 weeks .
Recombinant Rat TMEM176A is utilized in:
Mechanistic Studies: Investigating its role in ion channel regulation, dendritic cell differentiation, and immune responses .
Disease Models: Linked to hepatocellular carcinoma (via HCA112 alias) and long QT syndrome .
Drug Interaction Screens: Used to assess transcriptional responses to toxins, pharmaceuticals, and environmental agents .
Protein Interaction Mapping: Identified interactors include HIVEP1, TGM2, and HRSP12, suggesting roles in transcriptional regulation and signal transduction .
Studies using recombinant TMEM176A have revealed its sensitivity to diverse compounds:
| Compound | Effect on TMEM176A Expression | Study Model | Source |
|---|---|---|---|
| Clofibrate | Decreased | Rat hepatocytes | |
| Asbestos | Increased | Mouse lung tissue | |
| Cyclosporin A | Decreased | Human cell lines | |
| Rotenone | Increased | Rat neuronal cells |
These findings highlight its regulatory role in toxicological and pharmacological responses .
Immune Regulation: TMEM176A negatively regulates dendritic cell differentiation, impacting antigen presentation .
Environmental Stress Response: Upregulated by titanium dioxide and downregulated by perfluorinated compounds .
While recombinant TMEM176A has advanced in vitro studies, challenges persist:
Functional Complexity: Its exact biochemical role (e.g., ion channel vs. signaling scaffold) remains unresolved .
Species-Specific Variants: Cross-reactivity differences between rat, human, and mouse homologs necessitate cautious interpretation .
Ongoing research aims to elucidate its therapeutic potential in autoimmune diseases and cancer .
KEGG: rno:297077
UniGene: Rn.17071